EverSource Wealth Advisors’s Janux Therapeutics JANX Stock Holding History

EverSource Wealth Advisors’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$967	Buy	63 +54	+600%	+$782	﹤0.01%	3974
2026 Q1	$126	Sell	9 -47	-84%	-$644	﹤0.01%	4245
2025 Q4	$773	Sell	56 -100	-64%	-$2.35K	﹤0.01%	3776
2025 Q3	$3.81K	Buy	156 +16	+11%	+$390	﹤0.01%	3271
2025 Q2	$3.23K	Buy	140 +35	+33%	+$922	﹤0.01%	3327
2025 Q1	$2.83K	Buy	105 +97	+1,213%	+$3.66K	﹤0.01%	2760
2024 Q4	$428	Buy	+8	New	+$423	﹤0.01%	3247

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

EverSource Wealth Advisors's JANX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Janux Therapeutics (JANX) stake by 600% in Q2 2026, buying an estimated $782 and bringing the position to 63 shares worth $967. The position accounts for ﹤0.01% of the portfolio, ranked #3974.

EverSource Wealth Advisors first reported a position in JANX in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.81K in Q3 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

EverSource Wealth Advisors held 63 shares of Janux Therapeutics worth $967 as of Q2 2026.
EverSource Wealth Advisors bought 54 Janux Therapeutics shares in Q2 2026, an estimated $782.
Janux Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3974 holding.
EverSource Wealth Advisors first reported a position in Janux Therapeutics in Q4 2024 and has held it in 7 quarters since.
EverSource Wealth Advisors's Janux Therapeutics position peaked at $3.81K in Q3 2025.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.